Mosquito-borne Diseases Drug Development Pipeline Review, 2018
Summary
This report provides an overview of the pipeline landscape for mosquito-borne diseases and comprehensive information on the therapeutics under development and key players involved in therapeutic development for West Nile virus infections, Japanese encephalitis, yellow fever and malaria. It also features dormant and discontinued products.
West Nile infection, Japanese encephalitis and yellow fever are all caused by flaviviruses, whereas malaria is caused by a parasite (Plasmodium). Symptoms of West Nile infection include a fever, headache, body aches, skin rash, and swollen lymph glands. There are 18 products in development for this indication.
Japanese encephalitis affects the membranes around the brain. Symptoms include fever, headache, muscle pain, diarrhea, seizures, muscle weakness and paralysis. There are 17 products in development for this indication.
Yellow fever is an acute systemic illness (hemorrhagic fever). Symptoms include irregular heartbeats, bleeding, vomiting, coma, delirium, fever, headache and muscle aches. There are 15 products in development for this indication.
Malaria is a life-threatening blood disease. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. There are 206 products in development for this indication.
Molecular targets acted on by products in development for mosquito-borne diseases include interferon receptors, toll-like receptors and pathogen proteins such as Plasmodium falciparum merozoite surface proteins. Companies operating in this pipeline space include Sanaria, Medigen and Ology Bioservices.
Scope
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Mosquito-borne Diseases Drug Development Pipeline Review, 2018
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Mosquito-borne Diseases Report Coverage 8
2.2 West Nile Virus Infections - Overview 8
2.3 Japanese Encephalitis - Overview 8
2.4 Yellow Fever - Overview 8
2.5 Malaria - Overview 8
3 Therapeutics Development 9
3.1 West Nile Virus Infections 9
3.2 Japanese Encephalitis 14
3.3 Yellow Fever 18
3.4 Malaria 22
4 Therapeutics Assessment 38
4.1 West Nile Virus Infections 38
4.2 Japanese Encephalitis 44
4.3 Yellow Fever 47
4.4 Malaria 53
5 Companies Involved in Therapeutics Development 62
5.1 West Nile Virus Infections 62
5.2 Japanese Encephalitis 65
5.3 Yellow Fever 70
5.4 Malaria 74
6 Dormant Projects 102
6.1 West Nile Virus Infections 102
6.2 Japanese Encephalitis 104
6.3 Yellow Fever 105
6.4 Malaria 106
7 Discontinued Products 114
7.1 Japanese Encephalitis 114
7.2 Malaria 114
8 Product Development Milestones 116
8.1 West Nile Virus Infections 116
8.2 Yellow Fever 121
8.3 Malaria 124
9 Appendix 141
9.1 Methodology 141
9.2 Coverage 141
9.3 Secondary Research 141
9.4 Primary Research 141
9.5 Expert Panel Validation 141
9.6 Contact Us 142
9.7 Disclaimer 142
1.1 List of Tables
Table 1: Number of Products under Development for West Nile Virus Infections 9
Table 2: Number of Products under Development by Companies, West Nile Virus Infections 10
Table 3: Number of Products under Development by Universities/Institutes, West Nile Virus Infections 11
Table 4: Products under Development by Companies, West Nile Virus Infections 12
Table 5: Products under Development by Universities/Institutes, West Nile Virus Infections 13
Table 6: Number of Products under Development for Japanese Encephalitis 14
Table 7: Number of Products under Development by Companies, Japanese Encephalitis 15
Table 8: Number of Products under Development by Universities/Institutes, Japanese Encephalitis 16
Table 9: Products under Development by Companies, Japanese Encephalitis 17
Table 10: Products under Development by Universities/Institutes, Japanese Encephalitis 17
Table 11: Number of Products under Development for Yellow Fever 18
Table 12: Number of Products under Development by Companies, Yellow Fever 19
Table 13: Number of Products under Development by Universities/Institutes, Yellow Fever 20
Table 14: Products under Development by Companies, Yellow Fever 21
Table 15: Products under Development by Universities/Institutes, Yellow Fever 21
Table 16: Number of Products under Development for Malaria 22
Table 17: Number of Products under Development by Companies, Malaria 24
Table 18: Number of Products under Development by Universities/Institutes, Malaria 27
Table 19: Products under Development by Companies, Malaria 29
Table 20: Products under Development by Universities/Institutes, Malaria 33
Table 21: Number of Products by Stage and Target, West Nile Virus Infections 39
Table 22: Number of Products by Stage and Mechanism of Action, West Nile Virus Infections 40
Table 23: Number of Products by Stage and Route of Administration, West Nile Virus Infections 42
Table 24: Number of Products by Stage and Molecule Type, West Nile Virus Infections 43
Table 25: Number of Products by Stage and Target, Japanese Encephalitis 44
Table 26: Number of Products by Stage and Mechanism of Action, Japanese Encephalitis 44
Table 27: Number of Products by Stage and Route of Administration, Japanese Encephalitis 45
Table 28: Number of Products by Stage and Molecule Type, Japanese Encephalitis 47
Table 29: Number of Products by Stage and Target, Yellow Fever 48
Table 30: Number of Products by Stage and Mechanism of Action, Yellow Fever 50
Table 31: Number of Products by Stage and Route of Administration, Yellow Fever 51
Table 32: Number of Products by Stage and Molecule Type, Yellow Fever 53
Table 33: Number of Products by Stage and Target, Malaria 54
Table 34: Number of Products by Stage and Mechanism of Action, Malaria 57
Table 35: Number of Products by Stage and Route of Administration, Malaria 59
Table 36: Number of Products by Stage and Molecule Type, Malaria 61
Table 37: West Nile Virus Infections - Pipeline by CEL-SCI Corp 62
Table 38: West Nile Virus Infections - Pipeline by Ennaid Therapeutics LLC 62
Table 39: West Nile Virus Infections - Pipeline by Hawaii Biotech Inc 63
Table 40: West Nile Virus Infections - Pipeline by Hemispherx Biopharma Inc 63
Table 41: West Nile Virus Infections - Pipeline by Kineta Inc 64
Table 42: West Nile Virus Infections - Pipeline by Ology Bioservices Inc 64
Table 43: West Nile Virus Infections - Pipeline by Plex Pharmaceuticals Inc 65
Table 44: Japanese Encephalitis - Pipeline by Abivax SA 65
Table 45: Japanese Encephalitis - Pipeline by Adimmune Corp 66
Table 46: Japanese Encephalitis - Pipeline by Cadila Healthcare Ltd 66
Table 47: Japanese Encephalitis - Pipeline by Ennaid Therapeutics LLC 67
Table 48: Japanese Encephalitis - Pipeline by Indian Immunologicals Ltd 67
Table 49: Japanese Encephalitis - Pipeline by Kineta Inc 68
Table 50: Japanese Encephalitis - Pipeline by Livzon Pharmaceutical Group Inc 68
Table 51: Japanese Encephalitis - Pipeline by Panacea Biotec Ltd 69
Table 52: Japanese Encephalitis - Pipeline by Sinovac Biotech Ltd 69
Table 53: Yellow Fever - Pipeline by Bavarian Nordic A/S 70
Table 54: Yellow Fever - Pipeline by BioCryst Pharmaceuticals Inc 71
Table 55: Yellow Fever - Pipeline by Emergex Vaccines Ltd 71
Table 56: Yellow Fever - Pipeline by Ennaid Therapeutics LLC 71
Table 57: Yellow Fever - Pipeline by iBio Inc 72
Table 58: Yellow Fever - Pipeline by Ology Bioservices Inc 72
Table 59: Yellow Fever - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd 73
Table 60: Yellow Fever - Pipeline by Valneva SE 73
Table 61: Malaria - Pipeline by 4SC AG 74
Table 62: Malaria - Pipeline by AbbVie Inc 75
Table 63: Malaria - Pipeline by Agilvax Inc 75
Table 64: Malaria - Pipeline by Akshaya Bio Inc 75
Table 65: Malaria - Pipeline by AlfaSigma SpA 76
Table 66: Malaria - Pipeline by Allergy Therapeutics Plc 76
Table 67: Malaria - Pipeline by Altimmune Inc 77
Table 68: Malaria - Pipeline by Artificial Cell Technologies Inc 77
Table 69: Malaria - Pipeline by AstraZeneca Plc 78
Table 70: Malaria - Pipeline by Bharat Biotech Ltd 78
1.2 List of Figures
Figure 1: Number of Products under Development for West Nile Virus Infections 9
Figure 2: Number of Products under Development by Companies, West Nile Virus Infections 10
Figure 3: Number of Products under Development by Universities/Institutes, West Nile Virus Infections 11
Figure 4: Number of Products under Development for Japanese Encephalitis 14
Figure 5: Number of Products under Development by Companies, Japanese Encephalitis 15
Figure 6: Number of Products under Development by Universities/Institutes, Japanese Encephalitis 16
Figure 7: Number of Products under Development for Yellow Fever 18
Figure 8: Number of Products under Development by Companies, Yellow Fever 19
Figure 9: Number of Products under Development by Universities/Institutes, Yellow Fever 20
Figure 10: Number of Products under Development for Malaria 22
Figure 11: Number of Products under Development by Companies, Malaria 23
Figure 12: Number of Products under Development by Universities/Institutes, Malaria 26
Figure 13: Number of Products by Targets, West Nile Virus Infections 38
Figure 14: Number of Products by Stage and Targets, West Nile Virus Infections 38
Figure 15: Number of Products by Mechanism of Actions, West Nile Virus Infections 39
Figure 16: Number of Products by Stage and Mechanism of Actions, West Nile Virus Infections 40
Figure 17: Number of Products by Routes of Administration, West Nile Virus Infections 41
Figure 18: Number of Products by Stage and Routes of Administration, West Nile Virus Infections 41
Figure 19: Number of Products by Molecule Types, West Nile Virus Infections 42
Figure 20: Number of Products by Stage and Molecule Types, West Nile Virus Infections 43
Figure 21: Number of Products by Routes of Administration, Japanese Encephalitis 44
Figure 22: Number of Products by Stage and Routes of Administration, Japanese Encephalitis 45
Figure 23: Number of Products by Molecule Types, Japanese Encephalitis 46
Figure 24: Number of Products by Stage and Molecule Types, Japanese Encephalitis 46
Figure 25: Number of Products by Targets, Yellow Fever 47
Figure 26: Number of Products by Stage and Targets, Yellow Fever 48
Figure 27: Number of Products by Mechanism of Actions, Yellow Fever 49
Figure 28: Number of Products by Stage and Mechanism of Actions, Yellow Fever 49
Figure 29: Number of Products by Routes of Administration, Yellow Fever 50
Figure 30: Number of Products by Stage and Routes of Administration, Yellow Fever 51
Figure 31: Number of Products by Molecule Types, Yellow Fever 52
Figure 32: Number of Products by Stage and Molecule Types, Yellow Fever 52
Figure 33: Number of Products by Targets, Malaria 53
Figure 34: Number of Products by Stage and Targets, Malaria 54
Figure 35: Number of Products by Top 10 Mechanism of Actions, Malaria 56
Figure 36: Number of Products by Stage and Mechanism of Actions, Malaria 56
Figure 37: Number of Products by Routes of Administration, Malaria 58
Figure 38: Number of Products by Stage and Routes of Administration, Malaria 59
Figure 39: Number of Products by Top 10 Molecule Types, Malaria 60
Figure 40: Number of Products by Stage and Top 10 Molecule Types, Malaria 60
Global Cephalosporin Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 109
Cephalosporin is an antibiotic medication commonly prescribed to treat several different types of infections.
Cephalosporin originally derived from The fungus Acremonium, which was previously known as "Cephalosporium".
The global Cephalosporin market was valued at US$ 1380.7 million in 2023 and is anticipated to reach US$ 1346.9 million by 2030, witnessing a CAGR of -0.3% during The forecast period 2024-2030.
Market competition is intense. Qilu Antibiotics, Nectar Lifes......
Global Polymixin Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 120
According to our LPI (LP Information) latest study, the global Polymixin market size was valued at US$ 229.9 million in 2023. With growing demand in downstream market, the Polymixin is forecast to a readjusted size of US$ 291 million by 2030 with a CAGR of 3.4% during review period.
The research report highlights the growth potential of the global Polymixin market. Polymixin are expected to show stable growth in the future market. However, product differentiation, reducing costs, and sup......
Global Sepsis Partnering Market Research Report 2024
Published: 04-Jan-2024 Price: US 2900 Onwards Pages: 78
The Sepsis Partnering market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sepsis Partnering market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape......
Global Cephalosporin Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 156
According to our LPI (LP Information) latest study, the global Cephalosporin market size was valued at US$ 1350.7 million in 2023. With growing demand in downstream market, the Cephalosporin is forecast to a readjusted size of US$ 1319.6 million by 2030 with a CAGR of -0.3% during review period.
The research report highlights the growth potential of the global Cephalosporin market. Cephalosporin are expected to show stable growth in the future market. However, product differentiation, re......
Global Amoxicillin Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 127
According to our LPI (LP Information) latest study, the global Amoxicillin market size was valued at US$ 4512.7 million in 2023. With growing demand in downstream market, the Amoxicillin is forecast to a readjusted size of US$ 5711.7 million by 2030 with a CAGR of 3.4% during review period.
The research report highlights the growth potential of the global Amoxicillin market. Amoxicillin are expected to show stable growth in the future market. However, product differentiation, reducing co......
Global Metronidazole Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 136
According to our LPI (LP Information) latest study, the global Metronidazole market size was valued at US$ 110.5 million in 2023. With growing demand in downstream market, the Metronidazole is forecast to a readjusted size of US$ 106.6 million by 2030 with a CAGR of -0.5% during review period.
The research report highlights the growth potential of the global Metronidazole market. Metronidazole are expected to show stable growth in the future market. However, product differentiation, redu......
Global Drugs for Herpes Labialis (Oral Herpes) Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 131
According to our LPI (LP Information) latest study, the global Drugs for Herpes Labialis (Oral Herpes) market size was valued at US$ 2404.5 million in 2023. With growing demand in downstream market, the Drugs for Herpes Labialis (Oral Herpes) is forecast to a readjusted size of US$ 3402.2 million by 2030 with a CAGR of 5.1% during review period.
The research report highlights the growth potential of the global Drugs for Herpes Labialis (Oral Herpes) market. Drugs for Herpes Labialis (Ora......
Global Ampicillin Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 93
According to our LPI (LP Information) latest study, the global Ampicillin market size was valued at US$ 161.6 million in 2023. With growing demand in downstream market, the Ampicillin is forecast to a readjusted size of US$ 194.7 million by 2030 with a CAGR of 2.7% during review period.
The research report highlights the growth potential of the global Ampicillin market. Ampicillin are expected to show stable growth in the future market. However, product differentiation, reducing costs, a......
Global Acinetobacter Infections Treatment Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 101
According to our LPI (LP Information) latest study, the global Acinetobacter Infections Treatment market size was valued at US$ million in 2023. With growing demand in downstream market, the Acinetobacter Infections Treatment is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Acinetobacter Infections Treatment market. Acinetobacter Infections Treatment are expected to show stable ......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
